F1 ONCOLOGY INC has a total of 45 patent applications. It increased the IP activity by 86.0%. Its first patent ever was published in 2017. It filed its patents most often in WIPO (World Intellectual Property Organization), China and EPO (European Patent Office). Its main competitors in its focus markets biotechnology and pharmaceuticals are MILLEGEN, FELDAN BIO INC and EXUMA BIOTECH CORP.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 6 | |
#2 | China | 5 | |
#3 | EPO (European Patent Office) | 5 | |
#4 | Taiwan | 5 | |
#5 | Canada | 4 | |
#6 | Brazil | 3 | |
#7 | Israel | 3 | |
#8 | Republic of Korea | 3 | |
#9 | Mexico | 3 | |
#10 | Singapore | 3 | |
#11 | United States | 3 | |
#12 | Cuba | 2 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Peptides | |
#3 | Medical preparations | |
#4 | Therapeutic chemical compounds |
# | Name | Total Patents |
---|---|---|
#1 | Onuffer James Joseph | 36 |
#2 | Frost Gregory Ian | 36 |
#3 | Guibinga Ghiabe H | 21 |
#4 | Haerizadeh Farzad | 16 |
#5 | Kundu Anirban | 7 |
#6 | Gregory Ian Frost | 6 |
#7 | James Joseph Onuffer | 6 |
#8 | Ghiabe H Guibinga | 4 |
#9 | Farzad Haerizadeh | 2 |
#10 | Anirban Kundu | 2 |
Publication | Filing date | Title |
---|---|---|
SG11201907814SA | Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof | |
WO2018136570A1 | Chimeric antigen receptors against axl or ror2 and methods of use thereof | |
EP3571294A1 | Methods of transducing and expanding immune cells and uses thereof | |
CA3030003A1 | Methods and compositions for transducing lymphocytes and regulating the activity thereof | |
US2017356010A1 | Methods and compositions for transducing lymphocytes and regulating the activity thereof | |
KR20180127638A | Methods and compositions for transducing lymphocytes, and their controlled expansion |